(firstQuint)GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease.

 This is multicenter, randomized, double-blind, double-dummy, placebo-controlled, three-way cross-over, incomplete block design study to evaluation of 5 doses of GSK573719 administered once-daily and 3 doses of GSK573719 administered twice-daily over 14 days in subjects with COPD and will include tiotropium as an open-label active control.

 The pharmacokinetic profile of GSK573719 will also be evaluated.

.

 GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease@highlight

The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD.

